Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Fig. 5

Radiographical response of extramedullary disease after ide-cel treatment in index patient with pleural extramedullary disease. CT scans (transversal) showing radiographical disease course at day -6 (A), + 12 (B) and + 27 (C) after ide-cel infusion. At day + 12 an initial increase in pleural infiltrative mass and pleural effusion is observed, followed by decrease of both at day + 27

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us